Abbott India Ltd - Company Profile
Powered by 
All the data and insights you need on Abbott India Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Abbott India Ltd Strategy Report
- Understand Abbott India Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Abbott India Ltd (Abbott India), a subsidiary of Abbott Laboratories, discovers, develops, manufactures, and markets an array of branded generic pharmaceuticals, diagnostic tools, nutritional products, and diabetes and vascular devices. Its product portfolio encompasses multi-specialty drugs, vitamins, and products for the treatment of hypothyroidism, vertigo, epilepsy, depression and migraine. The company’s offerings also include vaccines for influenza, typhoid and diarrhoea. Abbott India develops pharmaceuticals in various formulations including tablets, injectables, liquids, ointments, granules, powder and capsules. The product range helps treat gynecological, gastroenterological, urological and neurological diseases, diabetes, pain, and infection. The company has a manufacturing facility in Goa, India. Abbott India is headquartered in Mumbai, Maharashtra, India.
Headquarters
India
Address
3-4 Corporate Park, Sion-Trombay Road, Chembur, Mumbai, Maharashtra, 400051
Website
www.abbott.co.in
Telephone
91 22 50461000
No of Employees
3,700
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ABBOTINDIA (NSE)
Revenue (2022)
$681.6M
8.7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
18.9%
(2022 vs 2021)
Market Cap*
$6.6B
Net Profit Margin (2022)
XYZ
9.3%
(2022 vs 2021)
* As of and is in US$
Abbott India Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Allergy: | Arachitol |
| Solspre | Brufen |
| Ebasil | Cremaffin |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | New Products/Services | In October, the company launched its new coronary imaging software, Ultreon. |
| 2022 | New Products/Services | In December, the company launched Navitor, a transcatheter aortic valve implantation (TAVI) system. |
| 2022 | Contracts/Agreements | In February, the company entered into collaboration with BeatO, Sugar.fit, PharmEasy, GOQii, 1MG, Zyla Health, Healthifyme and Fitterfly for diabetes management. |
Competitor Comparison
| Key Parameters | Abbott India Ltd | Aurobindo Pharma Ltd | Dr. Reddy's Laboratories Ltd | Cipla Ltd | Lupin Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Mumbai | Hyderabad | Hyderabad | Mumbai | Mumbai |
| State/Province | Maharashtra | Telangana | Telangana | Maharashtra | Maharashtra |
| No. of Employees | 3,700 | 15,690 | 24,832 | 26,615 | 18,971 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Sridhar Kadangode | Chief Financial Officer | Senior Management | 2023 | - |
| Munir Shaikh | Chairman | Non Executive Board | 2001 | - |
| Jyoti Saraph | Director - Finance | Senior Management | - | - |
| Sangeeta Shetty | Associate Director, Secretarial; Secretary | Senior Management | - | - |
| Jejoe Karankumar | Director - Medical Affairs | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward